Zoran Z. Gajic

Zoran Z. Gajic

Auto-generated profile, based on publicly available information

Zoran Z. Gajic

New York Genome Center, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Cell
Verified
Journal Article
Closed access
KHKevin Hadi
Kevin Hadi
XYXiaotong Yao
Xiaotong Yao
JBJulie M. Behr
Julie M. Behr
ADAditya Deshpande
Aditya Deshpande
CXCharalampos Xanthopoulakis
Charalampos Xanthopoulakis
MIMarcin Imielinski
Marcin Imielinski

16 March 2022 in Nature
Verified
Journal Article
Closed access
PDF file
MLMateusz Legut
Mateusz Legut
ZGZoran Gajic
Zoran Gajic
MGMaria Guarino
Maria Guarino
ZDZharko Daniloski
Zharko Daniloski
JRJahan A. Rahman
Jahan A. Rahman
NSNeville E. Sanjana
Neville E. Sanjana

8 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZGZoran Z. Gajic
Zoran Z. Gajic
ADAditya Deshpande
Aditya Deshpande
MLMateusz Legut
Mateusz Legut
MIMarcin Imieliński
Marcin Imieliński
NSNeville E. Sanjana
Neville E. Sanjana
Immune checkpoint blockade (ICB) has transformed the treatment of metastatic cancer but is hindered by variable response rates. A key unmet need is the identification of biomarkers that predict treatment response. To address this, we analyzed six whole exome sequencing cohorts with matched disease outcomes to identify genes and pathways predictive of ICB response. To increase detection power, we focus on genes and pathways that are significantly mutated following correction for epigenetic, replication timing, and sequence-based covariates. Using this technique, we identify several genes (BCLAF1, KRAS, BRAF, andTP53)and pathways (MAPK signaling, p53 associated, and immunomodulatory) as predictors of ICB response and develop the Cancer Immunotherapy Response CLassifiEr (CIRCLE). Compared to tumor mutational burden alone, CIRCLE led to superior prediction of ICB response with a 10.5% increase in sensitivity and a 11% increase in specificity. We envision that CIRCLE and more broadly the analysis of recurrently mutated cancer genes will pave the way for better prognostic tools for cancer immunotherapy.

21 October 2025 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
DSDaniel de Souza
Daniel de Souza
APAdhith Palla
Adhith Palla
RYRachel E. Yan
Rachel E. Yan
EGEric Alexander Grin
Eric Alexander Grin
MFMichael Farid
Michael Farid
DHDavid H. Harter
David H. Harter

27 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
XXXinhe Xue
Xinhe Xue
ZGZoran Z. Gajic
Zoran Z. Gajic
CCChristina M. Caragine
Christina M. Caragine
MLMateusz Legut
Mateusz Legut
CWConor Walker
Conor Walker
NSNeville E. Sanjana
Neville E. Sanjana
Summary: Recent massively-parallel approaches to decipher gene regulatory circuits have focused on the discovery of either cis -regulatory elements (CREs) or trans -acting factors. Here, we develop a scalable approach that pairs cis - and trans -regulatory CRISPR screens to systematically dissect how the key immune checkpoint PD-L1 is regulated. In human pancreatic ductal adenocarcinoma (PDAC) cells, we tile the PD-L1 locus using ∼25,000 CRISPR perturbations in constitutive and IFNγ-stimulated conditions. We discover 67 enhancer- or repressor-like CREs and show that distal CREs tend to contact the promoter of PD-L1 and related genes. Next, we measure how loss of all ∼2,000 transcription factors (TFs) in the human genome impacts PD-L1 expression and, using this, we link specific TFs to individual CREs and reveal novel PD-L1 regulatory circuits. For one of these regulatory circuits, we confirm the binding of predicted trans -factors (SRF and BPTF) using CUT&RUN and show that loss of either the CRE or TFs potentiates the anti-cancer activity of primary T cells engineered with a chimeric antigen receptor. Finally, we show that expression of these TFs correlates with PD-L1 expression in vivo in primary PDAC tumors and that somatic mutations in TFs can alter response and overall survival in immune checkpoint blockade-treated patients. Taken together, our approach establishes a generalizable toolkit for decoding the regulatory landscape of any gene or locus in the human genome, yielding insights into gene regulation and clinical impact.

5 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZGZoran Z. Gajic
Zoran Z. Gajic
ADAditya Deshpande
Aditya Deshpande
MLMateusz Legut
Mateusz Legut
MIMarcin Imieliński
Marcin Imieliński
NSNeville E. Sanjana
Neville E. Sanjana